financial statements 115 Hikma PHarmaceuticals Plc annual report 2011 5. exceptional items and intangible amortisation exceptional items are disclosed separately in the statement of comprehensive income to assist in the understanding of the Groups underlying performance.
2011 2010 $000 $000 acquisition related expenses 10,896 7,705 integration related expenses 5,472 16,368 7,705 gains on revaluation of previously held equity interests 7,176 inventory related adjustments 1,770 Exceptional items 18,138 529 intangible amortisation 8,998 7,401 Exceptional items and intangible amortisation 27,136 7,930 tax effect 6,374 3,666 Impact on profit for the year 20,762 4,264 intangible amortisation comprises the amortisation on intangible assets other than software.
acquisition and integration-related expenses are costs incurred in acquiring the Baxter Healthcare multi-source injectables business msi, socitde Promotion Pharmaceutique du maghreb s. a. Promopharm s. a, and elie Pharmaceuticals business, now called savanna.
acquisition-related expenses are included in the unallocated corporate expenses while integration-related expenses are included in segment results.
further details are set out in note 39 acquisition of subsidiaries.
acquisition-related expenses mainly comprised third party consulting services, legal and professional fees.
usD 10.1 million 31 December 2010: usD 7.7 million of costs have been classified as investing activities in the cash flow statement relating to the cash outflow in respect of acquisition and integration costs in the period.
the inventory-related adjustments reflect the fair value uplift of the inventory acquired as part of the msi acquisition refer to note 39. in the prior year, acquisition-related expenses related to transaction costs incurred in acquiring ibn al Baytar, al Dar al arabia and msi, forwhich the process of completion commenced in the second half of 2010. these were included in the unallocated corporate expenses.
Gains on revaluation of previously held equity interests related to gains arising from the remeasurement to fair value of the previously held equity interests in ibn al Baytar and al Dar al arabia.
these were included within other operating expenses net.
6. profit for the year Profit for the year has been arrived at after charging crediting : 2011 2010 $000 $000 net foreign exchange losses 111 6,309 research and development costs 31,218 23,608 loss on disposal of property, plant and equipment 22 376 gain on disposals of intangible assets 91 162 depreciation of property, plant and equipment 35,660 29,091 amortisation of intangible assets including software 11,343 9,342 inventories: cost of inventories recognised as an expense 330,537 247,774 write-down of inventories 12,271 13,076 staff costs see note 7 237,839 168,957 auditors remuneration see below 3,734 5,014 gains on revaluation of previously held equity interests 7,176 a more detailed analysis of the Groups auditors remuneration on a worldwide basis is provided below.
